Goldman Sachs’s IO Biotech IOBT Stock Holding History

Goldman Sachs’s Portfolio IOBT Stock Details IOBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-66,564	Closed	-$24.2K	–	6621
2025 Q3	$24.2K	Buy	+66,564	New	+$115K	﹤0.01%	6228

Other funds holding IOBT

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BPA

Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs's IOBT Position: Q4 2025 in Review

Goldman Sachs sold out of IO Biotech (IOBT) in Q4 2025, closing a stake of 66,564 shares — an estimated $24.2K sold.

Goldman Sachs first reported a position in IOBT in Q3 2025 and held it in 1 quarter. The position peaked at $24.2K in Q3 2025. 22 funds tracked by Wall St. Rank hold IOBT as of Q4 2025.

Goldman Sachs reported no remaining IO Biotech position as of Q4 2025 after selling out during the quarter.
Goldman Sachs sold 66,564 IO Biotech shares in Q4 2025, an estimated $24.2K.
Goldman Sachs first reported a position in IO Biotech in Q3 2025 and held it in 1 quarter.
Goldman Sachs's IO Biotech position peaked at $24.2K in Q3 2025.
22 funds tracked by Wall St. Rank held IO Biotech as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.